Notably, the rank order of ADU-S100-induced immunoregulatory DEGs was different when comparing treated B16 (Isg15 > Pdl1/Cd274 > Cox2/Ptgs2 > Arg2 > Nos2) vs. BPR20 (Nos2 > Pdl1/Cd274 > Isg15 > Arg2) melanomas (Supplementary Table 2), suggesting intrinsic differences in STING pathway signaling between these unrelated in vivo tumor models. This evidence concerns the gene PTGS2 and neoplasm.